Biolex pockets $30M for drug discovery work

Pittsboro, NC-based Biolex Therapeutics has raised $30 million in its third round with Investor Growth Capital of New York leading the way. Much of that money will go to advancing Locteron into Phase III clinical development in hepatitis C. Sunny Sharma, M.D., vice president with Investor Growth Capital, has joined the Biolex board.

"We are pleased to be a part of the Biolex story, which has some very interesting product and platform attributes," said Sharma. "Locteron has the potential to be a best-in-class interferon for the treatment of hepatitis C. We are also very excited about the company's glycosylation optimization technology and its application in various product opportunities."

- here's the release for more information

ALSO: Boulder, CO-based BaroFold has raised $12 million to advance its work developing improved protein therapeutics based on its PreEMT technology. Release

Suggested Articles

Bristol Myers Squibb may have bounced Jounce from its roster of inherited partners, but it’s hanging onto Anokion, a Swiss autoimmune-focused biotech.

The priority review action date sets Bristol Myers up to win approval for the bluebird-partnered anti-BCMA CAR-T therapy in late March.

The unidentified biotechs are drawn from the portfolio of a €150 million life science-focused fund that Index Ventures set up.